Skip to main content

Anti-Rheumatic Rx

Joint Disease in SLE Reconsidered

Jack Cush, MD

A new Frontiers in Immunology review from Ong, Wincup and colleagues, shows that lupus arthropathy is not a single uniform entity and it is biologically under-studied and clinically mismeasured, Moreover, the biology of lupus arthritis may shed light on choosing the best therapy for MSK

‘Tis the Season for Vaccination

Eric Dein, MD

As the leaves start changing color and spooky decorations populate neighborhood doorsteps, another autumnal tradition begins: vaccination counseling. Fall offers a golden opportunity to protect our patients before respiratory viruses fill our waiting rooms. In patients with rheumatologic

Dr. John Cush
@RheumNow
92 early (<2 yrs) systemic sclerosis pts were treated with #MTX; 79% diffuse SSc. At 3 mos, 34% of dcSSc ≥25% reduction in mRSS - increasing to 612% a@ 24 mos (29% at 24 mos ITT w/ non-responder imputation). GC did not improve skin. Dz progression seen w/ 75% of MTX monoTx D/C https://t.co/w5Gc3ntej0
Dr. John Cush
@RheumNow
Can DMARD Doses Be Safely Reduced for RA Patients? Close to 90% of patients with rheumatoid arthritis (RA) well controlled on targeted therapies were able to take 50% dosage reductions without experiencing worsened disease activity in a randomized trial, South Korean https://t.co/MyjZdRaGb4
Dr. John Cush
@RheumNow
Are Concerns Over Avacopan Efficacy Overblown? Avacopan (Tavneos), the complement pathway inhibitor for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), appeared strongly effective in an Italian registry study, maybe a step toward putting questions about https://t.co/4w2INKPFeT

Colchicine & Statins: A significant interaction?

Brian Jaros, MD

Aside from diarrhea, colchicine use is generally well tolerated, but its metabolism via the CYP3A4 cytochrome P450 enzyme pathway poses a potential risk of medication interaction. Statins are one of the most widely prescribed medication classes also metabolized by this pathway thus positing

Are Concerns Over Avacopan Efficacy Overblown?

MedPage Today

Avacopan (Tavneos), the complement pathway inhibitor for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), appeared strongly effective in an Italian registry study -- a step, maybe, toward setting to rest questions about its efficacy, if not its safety.

Dr. John Cush
@RheumNow
Can DMARD Doses Be Safely Reduced for RA Patients? Close to 90% of patients with rheumatoid arthritis (RA) well controlled on targeted therapies were able to take 50% dosage reductions without experiencing worsened disease activity in a randomized trial, South Korean https://t.co/GGPOBhVhJe
Dr. John Cush
@RheumNow
Don't Hold the Biologic or JAK with COVID-19 Vaccination A randomized clinical trial in inflammatory arthritis arthritis shows that temporarily holding biologic or Janus kinase (JAK) inhibitor therapy at the time of COVID-19 vaccination is not warranted. https://t.co/O9iJHEfp42

Treatment Landscape for Dermatomyositis Is Evolving

MedPage Today

After years of inactivity, therapeutic development for dermatomyositis has begun to move forward with several new therapies and therapeutic strategies.

"This is a very exciting time for the field because we're finally going to get some new treatments, and I think it will be helpful in

Dr. John Cush
@RheumNow
T-cell engager blinatumomab (CD3xCD19 TCE) was used for Deep B-cell depletion in 15 resistant RA pts (MDR-RA). @wk 12 9/15 CDAI LDA, 3/15 CDAI remission. Synovial B cells were depleted (4 of 5 biopsies) but not in lymph nodes. Later, 14/15 flared. No ICANs, 3/15 w/ CRS (gr 1) https://t.co/xLGZjkMmit
×